Company news

ArriVent BioPharma, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026

October 25, 2026

ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026

October 23, 2026

ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer

October 19, 2026

ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002

October 12, 2026

ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC

October 6, 2026

ArriVent BioPharma Reports Second Quarter 2026 Financial Results

August 12, 2026

ArriVent BioPharma Reports First Quarter 2026 Financial Results

May 10, 2026

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

May 7, 2026

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

March 17, 2026

ArriVent BioPharma Reports Full Year 2025 Financial Results

March 4, 2026

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

December 21, 2025

ArriVent BioPharma Reports Third Quarter 2025 Financial Results

November 9, 2025

ArriVent Appoints Brent S. Rice as Chief Commercial Officer

September 21, 2025

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

September 8, 2025

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

August 10, 2025

ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

July 20, 2025

ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants

June 30, 2025

ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

June 30, 2025

ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study

June 22, 2025

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

June 19, 2025

ArriVent BioPharma Reports First Quarter 2025 Financial Results

May 11, 2025

ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

April 27, 2025

ArriVent BioPharma Reports Full Year 2024 Financial Results

March 2, 2025

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

January 20, 2025

ArriVent BioPharma Reports Third Quarter 2024 Financial Results

November 13, 2024

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

September 8, 2024

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

August 13, 2024

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

August 11, 2024

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

June 4, 2024

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

May 15, 2024

ArriVent BioPharma Reports First Quarter 2024 Financial Results

May 7, 2024

ArriVent Appoints Kristine Peterson to its Board of Directors

April 21, 2024

ArriVent BioPharma Reports Full Year 2023 Financial Results

March 27, 2024

Decks